Ankur Drugs & Pharma Ltd. - Research Center
531683 ANKURDRUGS Group (T) BSE data
Results
|
Quarterly
|
Statement
|
|
More
|
|
Quarterly results in brief
(Rs crore)
|
Dec' 12 |
Sep' 12 |
Jun' 12 |
Mar' 12 |
Dec' 11 |
Sales |
36.12 |
35.51 |
33.27 |
37.94 |
38.50 |
Operating profit |
-1.52 |
-0.82 |
-2.89 |
-11.45 |
-7.42 |
Interest |
14.12 |
6.16 |
43.81 |
36.86 |
14.09 |
Gross profit |
-15.63 |
-6.97 |
-46.68 |
-48.30 |
-21.51 |
EPS (Rs) |
-21.12 |
-12.13 |
-32.83 |
-61.81 |
-18.94 |
Quarterly
results in details
|
Dec' 12 |
Sep' 12 |
Jun' 12 |
Mar' 12 |
Dec' 11 |
Other income |
0.01 |
0.01 |
0.02 |
0.01 |
0.01 |
Stock adjustment |
-1.10 |
-1.89 |
1.35 |
1.37 |
4.02 |
Raw material |
26.60 |
26.29 |
21.62 |
30.37 |
24.97 |
Power and fuel |
- |
- |
- |
- |
- |
Employee expenses |
5.02 |
5.12 |
5.78 |
6.54 |
7.14 |
Excise |
- |
- |
- |
- |
- |
Admin and selling expenses |
- |
- |
- |
- |
- |
Research and development expenses |
- |
- |
- |
- |
- |
Expenses capitalised |
- |
- |
- |
- |
- |
Other expenses |
7.12 |
6.82 |
7.41 |
11.10 |
9.78 |
Provisions made |
- |
- |
- |
- |
- |
Depreciation |
16.50 |
16.50 |
16.81 |
16.61 |
15.12 |
Taxation |
- |
- |
- |
31.27 |
- |
Net profit / loss |
-40.84 |
-23.47 |
-63.49 |
-119.55 |
-36.62 |
Extra ordinary item |
-8.71 |
- |
- |
-23.37 |
- |
Prior year adjustments |
- |
- |
- |
- |
- |
Equity capital |
19.34 |
19.34 |
19.34 |
19.34 |
19.34 |
Equity dividend rate |
- |
- |
- |
- |
- |
Agg.of non-prom. shares (Lacs) |
182.01 |
170.40 |
170.40 |
161.21 |
159.35 |
Agg.of non promotoholding (%) |
94.10 |
88.10 |
88.10 |
83.35 |
82.38 |
OPM (%) |
-4.21 |
-2.32 |
-8.69 |
-30.19 |
-19.28 |
GPM (%) |
-43.27 |
-19.63 |
-140.25 |
-127.28 |
-55.85 |
NPM (%) |
-113.04 |
-66.06 |
-190.74 |
-315.02 |
-95.11 |